Johnson & Johnson (NYSE:JNJ) had its price objective decreased by Credit Suisse Group from $154.00 to $151.00 in a research note released on Friday morning. Credit Suisse Group currently has an outperform rating on the stock.
Several other analysts also recently issued reports on JNJ. Leerink Swann reissued an outperform rating and issued a $160.00 price target (down previously from $175.00) on shares of Johnson & Johnson in a report on Wednesday, April 18th. They noted that the move was a valuation call. Jefferies Group set a $153.00 price target on Johnson & Johnson and gave the stock a buy rating in a report on Friday, April 13th. Deutsche Bank reissued a buy rating on shares of Johnson & Johnson in a report on Wednesday, April 18th. Wells Fargo reissued an outperform rating and issued a $150.00 price target (down previously from $160.00) on shares of Johnson & Johnson in a report on Wednesday, April 18th. Finally, Goldman Sachs set a $134.00 price target on Johnson & Johnson and gave the stock a sell rating in a report on Tuesday, April 17th. Five equities research analysts have rated the stock with a sell rating, eight have issued a hold rating and ten have issued a buy rating to the company’s stock. The company has an average rating of Hold and a consensus price target of $142.83.
Shares of NYSE JNJ opened at $126.66 on Friday. The company has a market capitalization of $339,816.38, a P/E ratio of 17.35, a P/E/G ratio of 1.96 and a beta of 0.74. Johnson & Johnson has a 12-month low of $121.54 and a 12-month high of $148.32. The company has a debt-to-equity ratio of 0.51, a quick ratio of 1.12 and a current ratio of 1.41.
Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Tuesday, April 17th. The company reported $2.06 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.00 by $0.06. The business had revenue of $20.01 billion for the quarter, compared to the consensus estimate of $19.50 billion. Johnson & Johnson had a return on equity of 30.05% and a net margin of 1.58%. The business’s revenue was up 12.6% on a year-over-year basis. During the same quarter last year, the business posted $1.83 EPS. research analysts forecast that Johnson & Johnson will post 8.13 earnings per share for the current year.
In other news, VP Paulus Stoffels sold 155,342 shares of Johnson & Johnson stock in a transaction on Thursday, February 15th. The stock was sold at an average price of $129.86, for a total transaction of $20,172,712.12. Following the transaction, the vice president now directly owns 357,906 shares in the company, valued at approximately $46,477,673.16. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. 0.22% of the stock is owned by insiders.
Hedge funds have recently modified their holdings of the company. Goodman Financial Corp acquired a new position in shares of Johnson & Johnson during the 4th quarter valued at $104,000. Stelac Advisory Services LLC acquired a new position in shares of Johnson & Johnson in the 4th quarter worth $108,000. Harding Loevner LP acquired a new position in shares of Johnson & Johnson in the 2nd quarter worth $106,000. Mountain Capital Investment Advisors Inc acquired a new position in shares of Johnson & Johnson in the 2nd quarter worth $124,000. Finally, Financial Gravity Companies Inc. acquired a new position in shares of Johnson & Johnson in the 4th quarter worth $143,000. Institutional investors own 67.23% of the company’s stock.
WARNING: This piece was first published by The Lincolnian Online and is owned by of The Lincolnian Online. If you are accessing this piece on another domain, it was illegally stolen and republished in violation of United States and international copyright & trademark laws. The original version of this piece can be viewed at https://www.thelincolnianonline.com/2018/04/23/credit-suisse-group-trims-johnson-johnson-jnj-target-price-to-151-00.html.
About Johnson & Johnson
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. Its Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, RoC, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.